Percy left us with an unforgettable gift. In order to stay current with newer developments, newer developments should be collected here.
Targeted agent, not approved for cholangiocarcinoma, but can be prescribed "off label."
Pembrolizumab (Keytruda) for patients whose disease has progressed after other treatments and with tumors that express the PD-L1 protein.
Keytruda works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells). By blocking this pathway, Keytruda may help the body’s immune system fight the cancer cells.
Keytruda's small molecules can penetrate the cell membrane to interact with targets inside a cell and are usually designed to interfere with the enzymatic activity of the target protein.
THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER